Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Diagnos ( (TSE:ADK) ) has issued an update.
DIAGNOS Inc. announced the closing of a non-brokered private placement, raising gross proceeds of $2,014,611 through the issuance of over 6.7 million units at $0.30 per unit. Each unit comprises one common share and one warrant, exercisable at $0.40 for 18 months. The funds will support the development and commercialization of AI-based screening services, regulatory affairs, and general operations. The placement is subject to regulatory approvals and all issued securities are under a statutory hold period until June 6, 2025.
More about Diagnos
DIAGNOS is a publicly traded Canadian corporation specializing in the early detection of critical health issues through artificial intelligence technology. The company utilizes its FLAIRE AI platform to develop applications like CARA, which enhances retinal images for effective real-time patient screening.
YTD Price Performance: 13.33%
Average Trading Volume: 180,655
Technical Sentiment Consensus Rating: Sell
Current Market Cap: C$32.35M
For an in-depth examination of ADK stock, go to TipRanks’ Stock Analysis page.
